Protein markers can help distinguish psoriatic arthritis from osteoarthritis Oral steroids put patients with inflammatory disease at high risk of infectionOral steroid use in patients with the inflammatory diseases polymyalgia rheumatica and/or giant cell arteritis significantly increased the risk of infection, and the risk increased with higher doses Canada to study the safety and effectiveness of biosimilars compared to reference biologic drugs Five-year study will examine real-world comparative efficacy and safety in rheumatologic conditions and inflammatory bowel disease. US FDA adds boxed warning about increased risk of death with gout drug Febuxostat (Uloric) increases risk of heart-related death and death from all causes compared with allopurinol Position statement on medical cannabis use in rheumatic disease Canadian Rheumatology Association provides guidance to ensure empathetic care and harm reduction Increased risk of serious vertebral fractures after stopping osteoporosis drug 'Drug holidays' cannot be safely taken in patients treated with denosumab Erelzi, second etanercept biosimilar, now available in Canada Approved for treatment of rheumatoid arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis Finasteride might cause rare serious muscle-related adverse effects Canadian product information is being updated to note this risk Finasteride might cause rare serious muscle-related adverse effects Canadian product information is being updated to note this risk Intra-articular triamcinolone of questionable benefit for knee osteoarthritis pain Injections show cartilage volume loss and no difference in knee pain compared to saline First Previous 10 11 12 13 14 Next Last
